# QuantHealth raises $45 million Series B for AI clinical trial simulations

> QuantHealth, a Tel Aviv startup building AI that simulates clinical trials before they run, has raised a $45 million Series B led by Qumra Capital, with backers including Pitango and Sanofi Ventures. The company says it has already simulated more than 600 trials, claiming up to 90% predictive accuracy in forecasting how they would play out. The problem it targets is one of the most expensive in medicine. Clinical trials routinely cost hundreds of millions and often fail late, after years of work. By modeling likely outcomes in advance, QuantHealth aims to help drugmakers pick better candidates and designs, and it says it already works with 12 of the world's top 20 pharmaceutical companies. The new money will go toward scaling adoption and R&D. It is a good example of AI moving beyond chatbots into the slow, high-stakes machinery of drug development, where even modest improvements in success rates translate into enormous savings and, potentially, faster cures.

_Section: [AI Funding Tracker](https://www.wortins.com/funding) · Source: FinSMEs · Published Thursday, August 6, 2026_

## Wortins' read

QuantHealth, a Tel Aviv startup building AI that simulates clinical trials before they run, has raised a $45 million Series B led by Qumra Capital, with backers including Pitango and Sanofi Ventures. The company says it has already simulated more than 600 trials, claiming up to 90% predictive accuracy in forecasting how they would play out. The problem it targets is one of the most expensive in medicine. Clinical trials routinely cost hundreds of millions and often fail late, after years of work. By modeling likely outcomes in advance, QuantHealth aims to help drugmakers pick better candidates and designs, and it says it already works with 12 of the world's top 20 pharmaceutical companies. The new money will go toward scaling adoption and R&D. It is a good example of AI moving beyond chatbots into the slow, high-stakes machinery of drug development, where even modest improvements in success rates translate into enormous savings and, potentially, faster cures.

## Source

[Read the full story at FinSMEs](https://www.finsmes.com/2026/08/quanthealth-raises-45m-in-series-b-funding.html)

## Related coverage

- [Nvidia and Palantir team up to run supply chains with AI, starting with Nvidia's own million-part operation](https://www.wortins.com/story/nvidia-and-palantir-team-up-to-run-supply-chains-with-ai-sta-4206093d) — [The Decoder](https://the-decoder.com/nvidia-and-palantir-team-up-to-run-supply-chains-with-ai-starting-with-nvidias-own-million-part-operation/)
- [Researchers used AI to build a WeChat worm that spreads through phone calls](https://www.wortins.com/story/researchers-used-ai-to-build-a-wechat-worm-that-spreads-thro-8bf3f469) — [The Next Web](https://thenextweb.com/news/wechat-worm-ai-calif-tencent-zero-click)
- [STAT+: Can AI fix the emergency room?](https://www.wortins.com/story/stat-can-ai-fix-the-emergency-room-a71d00ee) — [STAT](https://www.statnews.com/2026/09/09/scribe-emergency-room-fix-health-care-ai-prognosis/?utm_campaign=rss)
- [Inception launches Mercury 2.5 at 1,107 tokens per second](https://www.wortins.com/story/inception-launches-mercury-2-5-at-1-107-tokens-per-second-7999ed1b) — [TestingCatalog](https://www.testingcatalog.com/inception-launches-mercury-2-5-at-1-107-tokens-per-second/)
- [Powering AI is an architecture problem](https://www.wortins.com/story/powering-ai-is-an-architecture-problem-15281f16) — [MIT Technology Review](https://www.technologyreview.com/2026/09/10/1141649/powering-ai-is-an-architecture-problem/)
- [Top AI spenders cut per-employee costs by nearly 10 percent in August](https://www.wortins.com/story/top-ai-spenders-cut-per-employee-costs-by-nearly-10-percent--b31ffb0b) — [The Decoder](https://the-decoder.com/top-ai-spenders-cut-per-employee-costs-by-nearly-10-percent-in-august/)

---

_Curated and written by [Wortins](https://www.wortins.com) — The daily AI briefing. Every story links to its original source; the "Wortins read" on each is our own original analysis. [About Wortins & our editorial approach](https://www.wortins.com/about)._